The Oxidative Drug Combination for Suppressing KRAS G12D Inducible Tumour Growth.

Dinara BegimbetovaAssiya KukanovaFatima FazylKenzhekyz ManekenovaTalgat OmarovAgata N BurskaMedina KhamijanAlexandr GulyayevBakytgul YermekbayevaAbay MakishevTimur SalievKanat BatyrbekovChokan AitbayevZhanat SpatayevDos D Sarbassov

Published in: BioMed research international (2022)

The results of this study demonstrated that the combination of VC with a low dose of the oxidizing drug ATO led to the enhancement of the therapeutic effect. These findings suggest that the combined treatment using ATO and D-VC is a promising approach to overcome the limitation of drug selectivity and efficacy.

Keyphrases

low dose
adverse drug
high dose
drug induced